全文获取类型
收费全文 | 23305篇 |
免费 | 1748篇 |
国内免费 | 142篇 |
专业分类
耳鼻咽喉 | 197篇 |
儿科学 | 845篇 |
妇产科学 | 639篇 |
基础医学 | 3176篇 |
口腔科学 | 392篇 |
临床医学 | 2442篇 |
内科学 | 4797篇 |
皮肤病学 | 496篇 |
神经病学 | 2652篇 |
特种医学 | 501篇 |
外科学 | 2063篇 |
综合类 | 157篇 |
一般理论 | 37篇 |
预防医学 | 3031篇 |
眼科学 | 289篇 |
药学 | 1450篇 |
1篇 | |
中国医学 | 40篇 |
肿瘤学 | 1990篇 |
出版年
2024年 | 20篇 |
2023年 | 341篇 |
2022年 | 662篇 |
2021年 | 1199篇 |
2020年 | 754篇 |
2019年 | 990篇 |
2018年 | 1069篇 |
2017年 | 812篇 |
2016年 | 870篇 |
2015年 | 916篇 |
2014年 | 1193篇 |
2013年 | 1437篇 |
2012年 | 2112篇 |
2011年 | 2130篇 |
2010年 | 1099篇 |
2009年 | 926篇 |
2008年 | 1376篇 |
2007年 | 1296篇 |
2006年 | 1212篇 |
2005年 | 1055篇 |
2004年 | 901篇 |
2003年 | 759篇 |
2002年 | 656篇 |
2001年 | 106篇 |
2000年 | 84篇 |
1999年 | 89篇 |
1998年 | 107篇 |
1997年 | 93篇 |
1996年 | 73篇 |
1995年 | 80篇 |
1994年 | 50篇 |
1993年 | 58篇 |
1992年 | 50篇 |
1991年 | 45篇 |
1990年 | 42篇 |
1989年 | 33篇 |
1988年 | 47篇 |
1987年 | 34篇 |
1986年 | 45篇 |
1985年 | 25篇 |
1984年 | 42篇 |
1983年 | 24篇 |
1982年 | 28篇 |
1981年 | 34篇 |
1980年 | 24篇 |
1979年 | 20篇 |
1978年 | 17篇 |
1974年 | 22篇 |
1973年 | 17篇 |
1972年 | 17篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Cristina Torres‐Duarte Sara Hutton Carol Vines James Moore Gary N. Cherr 《Environmental toxicology》2019,34(3):294-302
Copper and copper oxide nanomaterials (nCuO) can enter the marine environment negatively impacting mussels, an environmental and commercially relevant organism. We analyzed the effects on the immune system of adult mussels exposed to soluble copper (CuSO4, 20‐50 μg/L) or nCuO (100‐450 μg/L). CuSO4 caused significant copper accumulation in gills and cell‐free hemolymph, while nCuO caused cell damage to gills and significant copper accumulation in hemocytes, the most abundant cells in the hemolymph. Both sources of copper caused cellular toxicity in hemocytes by increasing reactive oxygen species production and lysosome abundance, and decreasing multi‐drug resistance transporter activity. Though hemocyte abundance was not affected, their in‐vitro phagocytic activity decreased, explaining the slight (but not statistically significant) increase in bacterial proliferation in mussels exposed to the pathogenic bacteria Vibrio tubiashii following copper exposure. Thus, exposure to non‐lethal concentrations of CuSO4 or nCuO can potentially increase mussel susceptibility to bacterial infections. 相似文献
992.
Jason E. Farrar Paola Quarello Ross Fisher Kelly A. O'Brien Anna Aspesi Sara Parrella Adrianna L. Henson Nancy E. Seidel Eva Atsidaftos Supraja Prakash Shahla Bari Emanuela Garelli Robert J. Arceci Irma Dianzani Ugo Ramenghi Adrianna Vlachos Jeffrey M. Lipton David M. Bodine Steven R. Ellis 《American journal of hematology》2014,89(10):985-991
Diamond Blackfan anemia (DBA), a syndrome primarily characterized by anemia and physical abnormalities, is one among a group of related inherited bone marrow failure syndromes (IBMFS) which share overlapping clinical features. Heterozygous mutations or single‐copy deletions have been identified in 12 ribosomal protein genes in approximately 60% of DBA cases, with the genetic etiology unexplained in most remaining patients. Unlike many IBMFS, for which functional screening assays complement clinical and genetic findings, suspected DBA in the absence of typical alterations of the known genes must frequently be diagnosed after exclusion of other IBMFS. We report here a novel deletion in a child that presented such a diagnostic challenge and prompted development of a novel functional assay that can assist in the diagnosis of a significant fraction of patients with DBA. The ribosomal proteins affected in DBA are required for pre‐rRNA processing, a process which can be interrogated to monitor steps in the maturation of 40S and 60S ribosomal subunits. In contrast to prior methods used to assess pre‐rRNA processing, the assay reported here, based on capillary electrophoresis measurement of the maturation of rRNA in pre‐60S ribosomal subunits, would be readily amenable to use in diagnostic laboratories. In addition to utility as a diagnostic tool, we applied this technique to gene discovery in DBA, resulting in the identification of RPL31 as a novel DBA gene. Am. J. Hematol. 89:985–991, 2014. © 2014 Wiley Periodicals, Inc. 相似文献
993.
Monika Engelhardt Evangelos Terpos Martina Kleber Francesca Gay Ralph W?sch Gareth Morgan Michele Cavo Niels van de Donk Andreas Beilhack Benedetto Bruno Hans Erik Johnsen Roman Hajek Christoph Driessen Heinz Ludwig Meral Beksac Mario Boccadoro Christian Straka Sara Brighen Martin Gramatzki Alessandra Larocca Henk Lokhorst Valeria Magarotto Fortunato Morabito Meletios A. Dimopoulos Hermann Einsele Pieter Sonneveld Antonio Palumbo 《Haematologica》2014,99(2):232-242
Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B). 相似文献
994.
Sara Raponi Caterina Ilari Irene Della Starza Luca V. Cappelli Luciana Cafforio Alfonso Piciocchi Valentina Arena Paola Mariglia Francesca R. Mauro Massimo Gentile Giovanna Cutrona Riccardo Moia Chiara Favini Fortunato Morabito Davide Rossi Gianluca Gaidano Anna Guarini Ilaria Del Giudice Robin Foà 《British journal of haematology》2020,189(5):853-859
In chronic lymphocytic leukaemia (CLL), caution is warranted regarding the clinical implications of immunoglobulin variable heavy chain region (IGHV) rearrangements with a ‘borderline’ (BL) percentage of mutations (i.e. 97–97·9% IGHV identity). We analysed the IGHV mutational status in 759 untreated CLL patients (cohort 1). BL-CLL (n = 36, 5%) showed a time to first treatment (TFT) similar to that of M-CLL (n = 338) and significantly longer than that of UM-CLL (n = 385), despite the enrichment in subset #2 cases. In fact, CLLs belonging to subset #2 (n = 15/759, 2%) were significantly more frequent among BL-CLLs (n = 5/36, 14%), with a brief TFT. TFT of BL-CLL remained comparable to that of M-CLL also considering the 327 CLL patients evaluated at diagnosis. These findings were then validated in an independent cohort 2 of 759 newly diagnosed CLL patients (BL-CLL: n = 11, 1·4%) and in all newly diagnosed patients from cohorts 1 and 2 (n = 1 086, 84% stage A; BL-CLL: n = 47, 4·3%). BL-CLL at diagnosis showed a biological profile comparable to that of M-CLL with a low frequency of unfavourable prognostic markers, except for a significant enrichment in subset #2. Our data suggest that the prognosis of BL-CLL is good and similar to that of M-CLL, with the exception of subset #2 cases. 相似文献
995.
996.
Over the last decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment modality for relapsed/refractory B-cell malignancies in both children and adults. As an adoptive immune therapy, CAR-T cells have the potential to overcome disease that is resistant to chemo- and radiotherapy as well as represent a viable option for those who have already reached toxicity ceilings with standard therapies. CD19-directed CAR-T cell products have been licensed for use in paediatric B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse. Many challenges remain, rightly resulting in a heavily-mined research field. These include mitigating short-term immune-mediated toxicity, maintaining durability of responses, broadening treatment accessibility and extending its applicability to other malignant settings. In this review, dedicated to marking 60 years since the establishment of the British Society for Haematology, we will focus on the contribution of our community towards the success of CD19-directed CAR-T cell therapy in children. We will put current practice in CAR-T cell therapy into the context of future challenges to be addressed in order for it to fulfil its “game-changing” therapeutic potential. 相似文献
997.
Vera Adema Laura Palomo Andrea Toma Olivier Kosmider Francisco Fuster-Tormo Rocío Benito Rocío Salgado Esperanza Such María José Larrayoz Blanca Xicoy Jesus Maria Hernandez-Sanchez Paolo Maietta Alexander Neef Michaela Fontenay Mariam Ibañez Maria Diez-Campelo Sara Alvarez Jaroslaw P. Maciejewski Pierre Fenaux Francesc Sole 《British journal of haematology》2020,189(4):e133-e137
998.
Ana Dugic Sara Nikolic Steffen Mühldorfer Milutin Bulajic Raffaella Pozzi Mucelli Apostolos V. Tsolakis 《Scandinavian journal of gastroenterology》2020,55(5):517-527
AbstractBackground: Except for pancreas divisum (PD), the prevalence of anatomic variants of the main pancreatic duct (MPD) seems to be insufficiently investigated. To date, their role in the occurrence of pancreatic exocrine insufficiency (PEI) and morphological changes suggestive of chronic pancreatitis (CP) has remained unclear.Methods: A systematic review was performed, searching MEDLINE and Web of Science, limited to articles published between 1960 and 1 June 2019.Results: Our review included a total number of 3234 subjects. The most common variant of MPD was type 3, followed by type 1, indicating MPD drainage pattern into major papilla (MP) as the most frequent. A sub-variant of type 3, known as ‘reverse pancreas divisum’ had a prevalence of 2.2%. Type 4 variant- PD, was found in 6.4% of all cases. The most common sub-variant of PD was complete PD, followed by incomplete PD and variant with MPD as only pancreatic duct. Type 5 variant (including ansa pancreatica) was present in 2.9% of subjects. Apart from one study with a significantly higher frequency of morphological changes suggestive of CP in patients with ansa pancreatica, the studies stated no significant association between pancreatic disease and MPD variants. Furthermore, only one study examined the influence of MPD variants on exocrine pancreatic function. Although equivocal, this association is most likely found to be insignificant.Conclusion: To elucidate linkage between MPD variants and the occurrence of chronic pancreatitis and impairment of pancreatic exocrine function, further clinical investigations are warranted. 相似文献
999.